Mediolanum International Funds Ltd Has $7.70 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mediolanum International Funds Ltd lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,344 shares of the company’s stock after selling 3,558 shares during the quarter. Mediolanum International Funds Ltd owned 0.06% of Neurocrine Biosciences worth $7,704,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the period. Blue Trust Inc. raised its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. R Squared Ltd acquired a new position in Neurocrine Biosciences in the fourth quarter worth $61,000. UMB Bank n.a. raised its holdings in shares of Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after buying an additional 309 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its position in Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after buying an additional 157 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares in the company, valued at $338,445. This represents a 30.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the completion of the transaction, the director now directly owns 514,596 shares of the company’s stock, valued at $76,911,518.16. This represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 214,799 shares of company stock valued at $31,513,583 in the last quarter. 4.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

NBIX has been the subject of several research reports. Piper Sandler restated an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Raymond James reiterated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Wedbush restated an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Barclays raised their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $166.10.

Neurocrine Biosciences Price Performance

NBIX stock opened at $151.82 on Friday. The stock has a market capitalization of $15.37 billion, a P/E ratio of 40.70 and a beta of 0.33. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The business has a 50-day moving average of $136.97 and a 200-day moving average of $131.62.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.